Cargando…

Outpatient parenteral antimicrobial therapy (OPAT) in patients with cystic fibrosis

BACKGROUND: To determine complications during outpatient parenteral antimicrobial therapy (OPAT) administrated through a peripheral venous line, PICC-line or PORT-A-CATH (PAC). METHODS: Catheter related complications in patients with cystic fibrosis during OPAT were identified through a retrospectiv...

Descripción completa

Detalles Bibliográficos
Autores principales: Pedersen, Maya Graham, Jensen-Fangel, Søren, Olesen, Hanne Vebert, Tambe, San deep Prataprao, Petersen, Eskild
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4515313/
https://www.ncbi.nlm.nih.gov/pubmed/26212271
http://dx.doi.org/10.1186/s12879-015-1019-4
_version_ 1782382895431680000
author Pedersen, Maya Graham
Jensen-Fangel, Søren
Olesen, Hanne Vebert
Tambe, San deep Prataprao
Petersen, Eskild
author_facet Pedersen, Maya Graham
Jensen-Fangel, Søren
Olesen, Hanne Vebert
Tambe, San deep Prataprao
Petersen, Eskild
author_sort Pedersen, Maya Graham
collection PubMed
description BACKGROUND: To determine complications during outpatient parenteral antimicrobial therapy (OPAT) administrated through a peripheral venous line, PICC-line or PORT-A-CATH (PAC). METHODS: Catheter related complications in patients with cystic fibrosis during OPAT were identified through a retrospective review of patient files supplemented by an interview. RESULTS: In 64 treatment episodes with a peripheral venous line, 51 (79.7 %) used bolus injection and 13 (20.3 %) used infusion pump. 27 out of 51 (53.0 %) bolus injection episodes experienced complications, which required removal. None were observed for infusion pump treatments. The infectious complications requiring removal of peripheral venous line were 9 out of 23 (39.1 %) for the PICC line and 11 out of 26 (42.3 %) for the PAC. No anaphylaxis was observed during the OPAT treatments. CONCLUSIONS: Our data indicate that using an infusion pump to administer the antibiotic treatment minimized peripheral venous line complications. The frequency of complications leading to removal of the catheter is about the same for PICC-lines and PACs, but the average life-time of the latter is much longer. Allergic reactions are not a major problem. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12879-015-1019-4) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4515313
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-45153132015-07-27 Outpatient parenteral antimicrobial therapy (OPAT) in patients with cystic fibrosis Pedersen, Maya Graham Jensen-Fangel, Søren Olesen, Hanne Vebert Tambe, San deep Prataprao Petersen, Eskild BMC Infect Dis Research Article BACKGROUND: To determine complications during outpatient parenteral antimicrobial therapy (OPAT) administrated through a peripheral venous line, PICC-line or PORT-A-CATH (PAC). METHODS: Catheter related complications in patients with cystic fibrosis during OPAT were identified through a retrospective review of patient files supplemented by an interview. RESULTS: In 64 treatment episodes with a peripheral venous line, 51 (79.7 %) used bolus injection and 13 (20.3 %) used infusion pump. 27 out of 51 (53.0 %) bolus injection episodes experienced complications, which required removal. None were observed for infusion pump treatments. The infectious complications requiring removal of peripheral venous line were 9 out of 23 (39.1 %) for the PICC line and 11 out of 26 (42.3 %) for the PAC. No anaphylaxis was observed during the OPAT treatments. CONCLUSIONS: Our data indicate that using an infusion pump to administer the antibiotic treatment minimized peripheral venous line complications. The frequency of complications leading to removal of the catheter is about the same for PICC-lines and PACs, but the average life-time of the latter is much longer. Allergic reactions are not a major problem. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12879-015-1019-4) contains supplementary material, which is available to authorized users. BioMed Central 2015-07-27 /pmc/articles/PMC4515313/ /pubmed/26212271 http://dx.doi.org/10.1186/s12879-015-1019-4 Text en © Pedersen et al. 2015 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Pedersen, Maya Graham
Jensen-Fangel, Søren
Olesen, Hanne Vebert
Tambe, San deep Prataprao
Petersen, Eskild
Outpatient parenteral antimicrobial therapy (OPAT) in patients with cystic fibrosis
title Outpatient parenteral antimicrobial therapy (OPAT) in patients with cystic fibrosis
title_full Outpatient parenteral antimicrobial therapy (OPAT) in patients with cystic fibrosis
title_fullStr Outpatient parenteral antimicrobial therapy (OPAT) in patients with cystic fibrosis
title_full_unstemmed Outpatient parenteral antimicrobial therapy (OPAT) in patients with cystic fibrosis
title_short Outpatient parenteral antimicrobial therapy (OPAT) in patients with cystic fibrosis
title_sort outpatient parenteral antimicrobial therapy (opat) in patients with cystic fibrosis
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4515313/
https://www.ncbi.nlm.nih.gov/pubmed/26212271
http://dx.doi.org/10.1186/s12879-015-1019-4
work_keys_str_mv AT pedersenmayagraham outpatientparenteralantimicrobialtherapyopatinpatientswithcysticfibrosis
AT jensenfangelsøren outpatientparenteralantimicrobialtherapyopatinpatientswithcysticfibrosis
AT olesenhannevebert outpatientparenteralantimicrobialtherapyopatinpatientswithcysticfibrosis
AT tambesandeepprataprao outpatientparenteralantimicrobialtherapyopatinpatientswithcysticfibrosis
AT peterseneskild outpatientparenteralantimicrobialtherapyopatinpatientswithcysticfibrosis